Head-to-head evidence
Lurasidone vs Risperidone (Risperdal)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Schizophrenia
Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline
Lurasidone
Marketed by Sumitomo Pharma
NCT00549718 · Phase 3 · completed
The study randomized approximately 500 participants to lurasidone 40, 80, or 120 mg or placebo and used quadruple masking of participants, clinicians, investigators, and outcome assessors. Its clinical primary endpoint, change in total PANSS score over 6 weeks, favored lurasidone overall versus placebo and was statistically significant (p<0.05).
Risperidone (Risperdal)
Marketed by Johnson & Johnson
NCT00253136 · Phase 3 · completed
The study randomized 458 participants to double-blind risperidone or placebo, with change in the clinical PANSS score as the primary endpoint. Because the registry does not report whether this endpoint was met, the trial provides a well-controlled design but no assessable result.
Next expected readout: December 2026 · NCT06482554 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Lurasidone's landscape · Risperidone (Risperdal)'s landscape